Back to Journals » OncoTargets and Therapy » Volume 9

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China

Total article views   HTML views PDF downloads Totals
7,208 Dovepress* 6,640+ 1,252 7,892
PubMed Central* 568 194 762
Totals 7,208 1,446 8,654
*Since 20 October 2016

View citations on PubMed Central and Google Scholar